Journal of Microbiology and Biotechnology
The Korean Society for Microbiology and Biotechnology publishes the Journal of Microbiology and Biotechnology.
Journal of Microbiology and Biotechnology
Condition  Expression
When you enter More than two words, please use ‘and , or’ operation by means of putting ‘,(Comma Mark)’ between each word.

2012 ; 22(6): 856~865

AuthorRenee Cornford-Nairns, Grant Daggard, Trilochan Mukkur
AffiliationDepartment of Biological and Physical Sciences, University of Southern Queensland, Toowoomba, 4350 Queensland, Australia
TitleConstruction and Preliminary Immunobiological Characterization of a Novel, Non-Reverting, Intranasal Live Attenuated Whooping Cough Vaccine Candidate
PublicationInfo J. Microbiol. Biotechnol.2012 ; 22(6): 856~865
AbstractWe describe the construction and immunobiological properties of a novel whooping cough vaccine candidate, in which the aroQ gene, encoding 3-dehydroquinase, was deleted by insertional inactivation using the kanamycin resistance gene cassette and allelic exchange using a Bordetella suicide vector. The aroQ B. pertussis mutant required supplementation of media to grow but failed to grow on an unsupplemented medium. The aroQ B. pertussis mutant was undetectable in the trachea and lungs of mice at days 6 and 12 post-infection, respectively. Antigen-specific antibody isotypes IgG1 and IgG2a, were produced, and cell-mediated immunity [CMI], using interleukin-2 and interferon-gamma as indirect indicators, was induced in mice vaccinated with the aroQ B. pertussis vaccine candidate, which were substantially enhanced upon second exposure to virulent B. pertussis. Interleukin- 12 was also produced in the aroQ B. pertussis-vaccinated mice. On the other hand, neither IgG2a nor CMI-indicator cytokines were produced in DTaP-vaccinated mice, although the CMI-indicator cytokines became detectable post-challenge with virulent B. pertussis. Intranasal immunization with one dose of the aroQ B. pertussis mutant protected vaccinated mice against an intranasal challenge infection, with no pathogen being detected in the lungs of immunized mice by day 7 post-challenge. B. pertussis aroQ thus constitutes a safe, non-reverting, metabolite-deficient vaccine candidate that induces both humoral and cellmediated immune responses with potential for use as a single-dose vaccine in adolescents and adults, in the first instance, with a view to disrupting the transmission cycle of whooping cough to infants and the community.
Full-Text(PDF)
KeywordsBordetella pertussis, aroQ, live attenuated pertussis vaccine, cell-mediated immunity induction, antibody response, protection against pertussis
References
  1. Andrews, R., A. Herceg, and C. Roberts. 1997. Pertussis notifications in Australia, 1991 to 1997. Commun. Dis. Intell. 21: 145-148.
    Pubmed
  2. Canthaboo, C., L. Williams, D. K. Xing, and M. J. Corbel. 2000. Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines. Vaccine 19: 637-643.
    CrossRef
  3. Cohen, S. M. and M. W. Wheeler. 1946. Pertussis vaccine prepared with phase-I cultures grown in fluid medium. Am. J. Pub. Health 36: 371-376.
    CrossRef Pubmed Central
  4. Conway, M. A., L. Madrigal-Estebas, S. McClean, D. J. Brayden, and K. H. Mills. 2001. Protection against Bordetella pertussis infection following parenteral or oral immunisation with antigens entrapped in biodegradable particles: Effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 19: 1940-1950.
    CrossRef
  5. Cornford, R. A. 1998. Characterisation of the aroD and/or aroQ gene of Bordetella pertussis. BSc. Hons. Thesis, University of Southern Queensland, Toowoomba, Queensland, Australia.
  6. Cornford, R. A. 2003. A novel, genetically engineered intranasal whooping cough vaccine. PhD Thesis, University of Southern Queensland, Toowoomba, Queensland, Australia.
  7. de Melker, H. E., M. A. Conyn-van Spaendonck, H. C. Rumke, J. K. van Wijngaarden, F. R. Mooi, and J. F. P. Schellekens. 1997. Pertussis in The Netherlands: An outbreak despite high levels of immunization with whole-cell vaccine. Emerg. Infect. Dis. 3:175-178.
    Pubmed CrossRef Pubmed Central
  8. Elahi, S., J. Holmstro, and V. Gerdts. 2007. The benefits of using diverse animal models for studying pertussis. Trends Microbiol. 15: 462-468.
    Pubmed CrossRef
  9. Ermens, A. A. M., A. J. M. Bayens, A. C. M. van Gemert, and J. L. P. van Duijnhoven. 1997. Simple dot-blot method evaluated for detection of antibodies against extractable nuclear antigens. Clin. Chem. 43: 2420-2422.
    Pubmed
  10. Frohlich, B. T., E. R. De Bernardez Clark, G. R. Siber, and R. W. Swartz. 1995. Improved pertussis toxin production by Bordetella pertussis through adjusting the growth medium’s ionic composition. J. Biotech. 39: 205-219.
    CrossRef
  11. Fry, S. R., A. Y. Chen, G. Daggard, and T. K. Mukkur. 2008. Parenteral immunization of mice with a genetically inactivated pertussis toxin DNA vaccine induces cell-mediated immunity and protection. J. Med. Microbiol. 57: 28-35.
    Pubmed CrossRef
  12. Gold, M. S., S. Noonan, M. Osbourn, S. Precepa, and A. E. Kempe. 2003. Local reactions at the fourth dose of acellular pertussis vaccine in South Australia. Med. J. Aust. 179: 191-194.
    Pubmed
  13. Hoiseth, S. K. and B. A. D. Stocker. 1981. Aromatic-dependent Salmonella Typhimurium are non-virulent and effective as live vaccines. Nature 291: 238-239.
    Pubmed CrossRef
  14. He, Q. and J. Mertsola. 2008. Factors contributing to pertussis resurgence. Future Microbiol. 3: 329-339.
    Pubmed CrossRef
  15. Kolos, V., R. Menzies, and P. McIntyre. 2007. Higher pertussis hospitalization rates in indigenous Australian infants, and delayed vaccination. Vaccine 25: 588-590.
    Pubmed CrossRef
  16. Lalonde, G., P. D. O’Hanley, B. A. D. Stocker, and K. T. Denich. 1994. Characterisation of a 3-dehydroquinase gene from Actinobacillus pleuropneumoniae with homology to the eukaryotic genes qa-2 and QUTE. Mol. Microbiol. 11: 273-280.
    Pubmed CrossRef
  17. Leef, M., K. L. Elkin, J. Barbic, and R. D. Shahin. 2000. Protective immunity to Bordetella pertussis requires both B cells and CD4+ T cells for key functions other than specific antibody production. J. Exp. Med. 191: 1841-1852.
    Pubmed CrossRef Pubmed Central
  18. Locht, C., R. Antoine, D. Raze, N. Mielcarek, D. Hot, Y. Lemoine, and Mascart F. 2004. Bordetella pertussis: From functional genomics to intranasal vaccination. Int. J. Med. Microbiol. 293: 583-588.
    Pubmed CrossRef
  19. Mahon, B. P., M. T. Brady, and K. H. Mills. 2000. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: Implications for long-term immunity in children. J. Infect. Dis. 181: 2087-2091.
    Pubmed CrossRef
  20. Marshall, H. S., M. S. Gold, R. Gent, P. J. Quinn, L. Piotto, M. F. Clarke, and D. M. Roberton. 2006. Ultrasound examination of extensive limb swelling reactions after diphtheria-tetanusacellular pertussis or reduced-antigen content diphtheria-tetanusacellular pertussis immunization in preschool-aged children. Pediatrics 118: 1501-1509.
    Pubmed CrossRef
  21. Marzouqi, I., P. Richmond, S. Fry, J. Wetherall, and T. Mukkur. 2010. Development of improved vaccines against whooping cough: Current status. Hum. Vaccin. 6: 1-11.
    Pubmed CrossRef
  22. Mielcarek, N., G. Riveau, F. Remoue, R. Antoine, A. Capron, and C. Locht. 1998. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat. Biotechnol. 16: 454-457.
    Pubmed CrossRef
  23. Mielcarek, N., A.-S. Debrie, D. Raze, J. Bertout, C. Rouanet, A. B. Younes, et al. 2006. Live attenuated B. pertussis as a singledose nasal vaccine against whooping cough. PLOS Pathog. 2:e65.
    Pubmed CrossRef Pubmed Central
  24. Mills, K. H. G. 2001. Immunity to Bordetella pertussis. Microbes Infect. 3: 655-677.
    CrossRef
  25. Mooi, F., I. H. Van Loo, M. van Gent, Q. He, M. J. Bart, K. J. Heuvelman, et al. 2009. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg. Infect. Dis. 15: 1206-1213.
    Pubmed CrossRef Pubmed Central
  26. Morbidity and Mortality Weekly Report. 2011. General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Recommendations and Reports. Vol. 60, No. 2.
  27. Mukkur, T. K., G. H. McDowell, B. A. D. Stocker, and A. K. Lascelles. 1987. Protection against experimental salmonellosis in mice and sheep by immunisation with aromatic-dependent Salmonella Typhimurium. J. Med. Microbiol. 24: 11-19.
    Pubmed CrossRef
  28. Nasso, M., G. Fedele, F. Spencieri, R. Palazzo, P. Costantino, R. Rappuoli, et al. 2011. Genetically detoxified pertussis induces Th1/Th17 immune response through MAPKs and IL-10dependent mechanisms. J. Immunol. 183: 1892-1899.
    Pubmed CrossRef
  29. National Notifiable Diseases Surveillance System. 2011. Available at http://www9.health.gov.au/cda/Source/Rpt_3.cfm, accessed4/3/2011.
  30. Olson, L. C. 1975. Pertussis. Medicine (Baltimore) 54: 427-469.
    Pubmed CrossRef
  31. Parkhill, J., M. Sebaihia, A. Preston, L. D. Murphy, N. Thomson, D. E. Harris, et al. 2003. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat. Genet. 35: 32-40.
    Pubmed CrossRef
  32. Pertussis [whooping cough]: Outbreaks. http://www.cdc.gov/pertussis/outbreaks.html. Accessed 14 June 2011.
  33. Quinn, P., M. Gold, J. Royle, J. Buttery, J. P. Richmond, P. McIntyre, et al. 2011. Recurrence of extensive injection site reactions following DTPa or dTpa vaccine in children 406 years old. Vaccine 29: 4230-4237.
    Pubmed CrossRef
  34. Rennels, M. B., M. A. Deloria, M. E. Pichichero, G. A. Losonsky, J. A. Englund, B. D. Meade, et al. 2000. Extensive swelling after booster doses of acellular pertussis-tetanusdiphtheria vaccines. Pediatrics 1: e1-e12.
  35. Roberts, M., D. Maskell, P. Novotny, and G. Dougan. 1990. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infect. Immun. 58: 732-739.
    Pubmed Pubmed Central
  36. Rowe, J., S. T. Yerkovich, P. Richmond, D. Suriyaarachchi, E. Fisher, L. Feddema, et al. 2005. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4- to 6-yearold children. Infect. Immun. 73: 8130-8135.
    Pubmed CrossRef Pubmed Central
  37. Rossetti, T. R. 1997. Cloning the aroD gene of Bordetella pertussis. BSc. Hons. Thesis, University of Southern Queensland, Toowoomba, Queensland, Australia.
  38. Sambrook, J., E. F. Fritsch, and Maniatis, T. 1989. Molecular Cloning: A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
  39. Schellekens, J., C. H. von Konig, and P. Gardner. 2005. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr. Infect. Dis. J. 24: 721-728.
    Pubmed CrossRef
  40. Shahin, R., M. Leef, J. Eldridge, M. Hudson, and R. Gilley. 1995. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly[DL-lactide-co-glycolide] microspheres. Infect. Immun. 63: 1195-1200.
    Pubmed Pubmed Central
  41. Stainer, D. W. and M. J. Scholte. 1971. A simple and chemically defined medium for the production of phase I Bordetella pertussis. J. Gen. Microbiol. 34: 778-784.
  42. Towbin, H., T. Stachelin, and J. Gordon. 1979. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. USA 76: 4350-4354.
    CrossRef
  43. Verma, N. K. and A. A. Lindberg. 1991. Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: Deletion mutations in the aroA and the aroD genes. Vaccine 9: 6-9.
    CrossRef
  44. Wearing, H. J. and P. Rohani. 2009. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog. 5: e1000647.
    Pubmed CrossRef Pubmed Central
  45. Weiss, A. A. and E. L. Hewlett. 1986. Virulence factors of Bordetella pertussis. Annu. Rev. Microbiol. 40: 661-686.
    Pubmed CrossRef
  46. Wendelboe, A. M., E. Njamkepo, A. Bourillon, D. D. Floret, J. Gaudelus, M. Gerber, et al. 2007. Infant Pertussis Study Group. Transmission of Bordetella pertussis to young infants. Pediatr. Infect. Dis. J. 26: 293-299.
    Pubmed CrossRef
  47. Rieber, N., A. Graf, D. Hartl, S. Urschel, B. H. Belohradsky, and J. Liese. 2011. Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response. PLoS ONE 6: e17271.
    Pubmed CrossRef Pubmed Central
Copyright © 2009 by the Korean Society for Microbiology and Biotechnology.
All right reserved. Mail to jmb@jmb.or.kr
Online ISSN: 1738-8872    Print ISSN: 1017-7825    Powered by INFOrang.co., Ltd